Form 4: Alkermes EVP Gaffin Reports Share Transactions

Alkermes plc's EVP, CLO, David Joseph Gaffin, reported the acquisition of 6,866 ordinary shares and the disposition of 3,049 shares for tax purposes.

Summary

• David Joseph Gaffin, EVP, CLO of Alkermes, Inc., reported transactions involving Alkermes plc ordinary shares.
• On February 26, 2026, Gaffin acquired 6,866 ordinary shares, likely through the vesting of restricted stock units.
• Concurrently, Gaffin disposed of 3,049 ordinary shares at a price of $30.73 per share, which was likely for tax withholding related to the share acquisition.
• Following these transactions, Gaffin directly beneficially owns 239,694 ordinary shares.
• Gaffin also reported an acquisition of 6,866 Restricted Stock Unit (RSU) awards, with each RSU representing a contingent right to receive one ordinary share.
• These RSU awards vest in four equal annual installments, commencing on February 26, 2025.
• Gaffin now directly beneficially owns 13,732 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation-related transactions. The acquisition of shares through RSU vesting indicates continued alignment of executive interests with shareholders, while the tax-related sale is a standard practice.

Positives

• The acquisition of 6,866 ordinary shares, likely through the vesting of restricted stock units, indicates continued equity ownership by a key executive.
• The executive's total direct beneficial ownership of ordinary shares remains substantial at 239,694 shares.

Negatives

• The disposition of 3,049 shares, even if for tax purposes, represents a reduction in direct shareholding.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting schedule of the restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, providing transparency into executive equity movements. These transactions, particularly those related to RSU vesting and tax withholding, are common occurrences in executive compensation structures within the pharmaceutical and biotechnology industry, reflecting standard equity incentive plans.

Comparison to Industry Standards

• These types of transactions (vesting of RSUs and subsequent sale for tax withholding) are standard practice across publicly traded companies, including peers in the pharmaceutical sector like Pfizer, Johnson & Johnson, or Merck.
• The specific number of shares and value are particular to Alkermes and the executive's compensation package, but the mechanism is globally consistent for equity-based compensation.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity holdings and compensation.
• Employees: Reflects standard executive compensation practices, potentially influencing broader compensation strategies.

Next Steps

• Future vesting installments for the Restricted Stock Unit Award will occur annually, commencing on February 26, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and a subsequent sale of shares for tax withholding. Such transactions are standard and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Alkermes plc, ALKS, Form 4, Insider Trading, David Joseph Gaffin, Restricted Stock Units, Share Acquisition, Share Disposition, Executive Compensation